Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

McLean Hospital and Repligen announce results of brain imaging study of secretin

01.11.2002


Secretin is active in a brain region implicated in autism



Researchers from the Brain Imaging Center at McLean Hospital and Repligen Corporation (Nasdaq: RGEN) reported today the results of a clinical trial designed to assess the neurological activity of secretin by functional magnetic resonance imaging (fMRI). The results demonstrate for the first time in humans, that secretin is active in the central nervous system and that it potentiates activity in the amygdala, a region of the brain involved in social integration and implicated in autism. The findings were presented today by Deborah Yurgelun-Todd, Ph.D., of McLean Hospital, the study’s Principal Investigator, at the International Meeting for Autism Research, a satellite meeting of the Society for Neuroscience.

"Our results demonstrate for the first time that secretin is a neuroactive peptide in humans and that it acts on a brain region known to be important for social interaction," stated Yurgelun-Todd, Director of Cognitive Neuroimaging at the Brain Imaging Center at McLean Hospital. "These findings suggest that secretin may have a role in modulating certain social behavior in humans."


The study was a double-blind, placebo-controlled clinical trial in 12 healthy men. Each subject was presented with a series of pictures of faces with either a neutral, happy or fearful facial expression to establish a baseline response. Following an injection of either secretin or a placebo, the subjects were again presented with the series of facial expressions. Throughout the experiment, the activation of the amygdala was recorded with MRI. There was a significant activation (p=0.001) of the right amygdala by secretin when the subjects viewed pictures of a fearful face compared to both the placebo group and the baseline response to the pictures in the secretin group. By contrast, there was no difference in amygdala activation when subjects viewed pictures of neutral or happy faces. Failure to activate the amygdala when viewing fearful faces is a characteristic of people with autism and patients with amygdala damage. The current study was initiated as part of ongoing research efforts to understand secretin as a neurologically active peptide. Repligen previously reported a finding that treatment of rats with secretin specifically activates the neurons in the amygdala. Repligen is currently developing secretin for autism in a Phase 3 clinical trial program.

"These studies show that secretin is active in a part of the human brain involved in social interaction and potentiates its activity during a social task known to be difficult for people with autism," stated Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen Corporation. "These data provides a plausible biological mechanism for the improvements in social interaction we observed in our Phase 2 clinical trial."

The Amygdala and the Social Deficits of Autism

The amygdala is part of a complex neural system that is critical for ascribing emotional value to stimuli and influencing affective responsiveness and emotional learning. One of the core deficits of autism is impaired reciprocal social interaction, including eye contact, joint attention and an inability to deduce the mental states of others from facial expressions. Reduced activation of the amygdala in patients with autism has been documented using fMRI with specific impairment noted in their ability to respond to facial expressions of fear. Other studies indicate that patients with either surgical or congenital amygdala damage show similar face recognition defects. Lack of activation of the amygdala is recognized as an important correlate of the social deficits of autism.

Repligen’s President and CEO Walter C. Herlihy, Ph.D. also presented data from its Phase 2 clinical trial. The Phase 2 study evaluated three administrations of secretin or a placebo in 126 patients aged 3 years to 6 years 11 months with moderate to severe symptoms of autism and gastrointestinal disorders. The primary finding of the Phase 2 clinical trial was that younger children, 3 and 4 year olds, showed improvements in reciprocal social interaction as judged by a standardized clinical instrument for the assessment of autistic symptoms. Repligen is currently conducting a Phase 3 clinical trial of secretin for the improvement of reciprocal social interaction in young children with autism.


About McLean Hospital
McLean Hospital maintains the largest research program of any private, U.S. psychiatric hospital. It is the largest psychiatric teaching facility of Harvard Medical School, an affiliate of Massachusetts General Hospital and a member of Partners HealthCare. The Brain Imaging Center at McLean is one of the largest imaging centers in the world, actively engaged in clinical research studies of brain function. Researchers at McLean were part of the team that first identified regional abnormalities in brain activation in patients with schizophrenia and in normal aging, as well as regional changes in blood flow and metabolism in patients with Alzheimer’s disease.

About Repligen Corporation
Repligen Corporation is a biopharmaceutical company committed to being the leader in the development of new drugs for pediatric developmental disorders including autism, immune and metabolic disorders. Repligen has a specialty pharmaceuticals business comprised of rProtein ATM and SecreFloTM, the profits from which will be used to support the development of our proprietary products. rProtein ATM is a consumable reagent used by the pharmaceutical industry to produce a class of drugs called monoclonal antibodies and SecreFloTM, secretin for injection, is marketed to gastroenterologists for pancreatic assessment. Repligen’s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

Renee L. Connolly | EurekAlert!

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>